Propanc Biopharma (NASDAQ:PPCB) Posts Earnings Results

Propanc Biopharma (NASDAQ:PPCB – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($12.22) earnings per share (EPS) for the quarter, FiscalAI reports.

Propanc Biopharma Stock Down 0.3%

Propanc Biopharma stock traded down $0.01 during trading hours on Friday, hitting $1.92. The stock had a trading volume of 9,307 shares, compared to its average volume of 39,572. The business’s 50 day simple moving average is $4.57 and its 200-day simple moving average is $20.32. Propanc Biopharma has a one year low of $1.63 and a one year high of $315.00. The stock has a market cap of $1.21 million, a price-to-earnings ratio of -0.01 and a beta of 3.55.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Check Out Our Latest Report on Propanc Biopharma

Propanc Biopharma Company Profile

(Get Free Report)

Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen.

Read More

Earnings History for Propanc Biopharma (NASDAQ:PPCB)

Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.